Ignite Creation Date:
2025-12-18 @ 4:24 AM
Ignite Modification Date:
2025-12-18 @ 4:24 AM
Study NCT ID:
NCT00759291
Status:
None
Last Update Posted:
2023-02-21 00:00:00
First Post:
2008-09-24 00:00:00
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome
Sponsor:
None
Organization:
Study Overview
Official Title:
The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome
Status:
None
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
We hypothesize that acipimox, by decreasing plasma FFA concentrations, will augment endothelium-dependent vasodilation in conduit vessels and insulin-mediated vasodilation in forearm resistance arterioles in vivo, whole-body insulin sensitivity, and AKT (also known as Protein Kinase B) and endothelial nitric oxide synthase (eNOS) phosphorylation in skin biopsy specimens ex vivo, when compared with placebo.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: